UK markets closed

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.66+0.27 (+3.65%)
At close: 04:00PM EDT
7.75 +0.09 (+1.17%)
After hours: 07:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.39
Open7.47
Bid7.62 x 300
Ask7.70 x 500
Day's range7.28 - 7.72
52-week range2.69 - 7.72
Volume1,258,232
Avg. volume541,922
Market cap473.174M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)-1.37
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.00
  • GlobeNewswire

    Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

    - Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Ti

  • GlobeNewswire

    Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

    – Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT06283589), with topline data expected in Q4 2024 – – Launched global patient registry (PROPEL) in partnership with GACI Global to advance understanding of ENPP1 Deficiency and infantile-onset ABCC6 Deficiency (NCT06302439) – – Cash, cash equi

  • GlobeNewswire

    Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

    - Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscula